Company profile for Helicore Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Helicore Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel weight-loss therapeutics. Its lead candidate, HCR-188, is a first-in-class biologic GIP antagonist with a differentiated mechanism of action. Advancing to clinical trials in early 2025, HCR-188 will be tested as both a monotherapy and in combination with GLP-1 for induction and maintenance treatment. Following a $65M Series A fin...
Helicore Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel weight-loss therapeutics. Its lead candidate, HCR-188, is a first-in-class biologic GIP antagonist with a differentiated mechanism of action. Advancing to clinical trials in early 2025, HCR-188 will be tested as both a monotherapy and in combination with GLP-1 for induction and maintenance treatment. Following a $65M Series A financing in January 2024, Helicore is poised to bring innovative solutions to the weight-loss treatment landscape.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1825 South Grant Street San Mateo, CA 94402
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/03/25/3048810/0/en/Helicore-Biopharma-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-HCR-188-a-First-in-Class-GIP-Antagonist-for-the-Treatment-of-Obesity.html

GLOBENEWSWIRE
25 Mar 2025

https://www.globenewswire.com/news-release/2025/01/28/3016188/0/en/Helicore-Biopharma-Emerges-from-Stealth-to-Continue-Advancing-Portfolio-of-First-in-Class-GIP-Antagonists-for-Obesity-and-Related-Conditions.html

GLOBENEWSWIRE
28 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty